{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 283,
  "pageCount": 415,
  "prevPage": 282,
  "nextPage": 284,
  "slideType": "villain_critique",
  "function": "name_villain",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses direct quotes from a KOL to build a case against the safety profile of the drug.",
  "elementsJson": [
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/283",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-283",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "We don't understand rare findings in rare diseases. We don't have the numbers out there. You don't realize this 1% or 2% risk until you have 100 patients together.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2ae-02eb7b528998",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.86,
        "x": 0.07,
        "y": 0.62
      },
      "kind": "paragraph",
      "text": "Expects safety signal to emerge similar to Zafgen when Vykat is used more broadly than in small cherry-picked trials. Transcript regarding the difficulty of identifying rare risks in small cohorts.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "484924ce-cfc8-4a61-b9c2-6da74044ac83",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.86,
        "x": 0.07,
        "y": 0.35
      },
      "kind": "paragraph",
      "text": "Won't use Vykat – worried about safety and adverse effects, cardiac events in particular. Q&A transcript highlighting concerns about Zafgen-like safety failures.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "965b2487-91b0-41d8-a3ed-601a8c7b36d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "No, I won't [use it] because of Zafgen...we find out oh, six months from now...they all of a sudden have cardiomyopathy or seizures....I'm concerned about safety. — Trial investigator and physician; one of the leading KOL's in the PWS field",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2ae-04afb4559a3c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8dd811c5-f668-4a5f-a7fc-ad7ae449a41f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "Trial investigator #1: Extremely concerned about diabetes, cardiac, and neurological safety signals emerging as more patients use it, similar to the fatalities that led to the termination of the Zafgen drug",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c5bbc65-03f0-424b-b386-fc7654efdf86",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Villain slide",
      "slug": "villain-slide",
      "agent": null,
      "layer": "slide",
      "matchId": "06a6ef36-1f6d-4321-8e78-33be6f5b805e",
      "evidence": "Trial investigator #1 expressed extreme concern about safety signals emerging with Vykat, similar to the fatalities that led to the termination of the Zafgen drug.",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "antagonist-introduction",
      "slug": null,
      "matchId": "bcf779e6-6788-40e4-830b-25a04de93fde",
      "evidence": "The slide frames the drug/company as a safety risk by introducing a critical expert voice.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}